Biotech News

Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance

Protagenic Therapeutics (PTIX)Protagenic Therapeutics2025-08-22 17:25 ESTSEC filing

Delay Attributable to Merger-Related Financial Consolidation

NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced that it expects to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 in the near...

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

IKTInhibikase Therapeutics2026-08-11 20:01 EST

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

ADXNAddex Therapeutics2026-06-25 05:00 EST

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

ADXNAddex Therapeutics2026-06-22 05:00 EST

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

AXSMAxsome2026-06-01 11:00 EST

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

View all latest news

Protagenic Therapeutics

Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.

Recent company news

PTIXProtagenic Therapeutics2026-05-19 08:15 EST

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

PTIXProtagenic Therapeutics2026-04-23 08:15 EST

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

PTIXProtagenic Therapeutics2026-03-17 08:00 EST

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

PTIXProtagenic Therapeutics2026-03-10 08:00 EST

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

PTIXProtagenic Therapeutics2025-12-09 08:46 EST

Results from Phase 1 Multiple-Dose Study of PT00114

Stock data

Close: 0.80 USD
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States